<DOC>
	<DOCNO>NCT00045357</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop tumor cell grow . Treating person 's white blood cell laboratory reinfusing may cause strong immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness biological therapy treat patient metastatic melanoma .</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose autologous CD4+ antigen-specific T-cells cellular adoptive immunotherapy patient metastatic melanoma . - Determine safety toxicity regimen patient . - Determine duration vivo persistence adoptively transfer CD4+ antigen-specific T-cell clone patient . Secondary - Determine antitumor effect regimen patient . OUTLINE : This dose-escalation study . Patients undergo leukapheresis collect peripheral blood mononuclear cell . CD4+ antigen-specific T-cell clone generate next 2-3 month use immunogenic peptide MART1 , tyrosinase , gp100 . Patients receive autologous CD4+ antigen-specific T-cells IV 30 minute . Cohorts 3-6 patient receive escalate dos autologous CD4+ antigen-specific T-cells maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow day 1 3 post T-cell infusion , weekly 12 week . PROJECTED ACCRUAL : A total 3-18 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma HLA type express one follow class II allele : DRB1*0401 DRB1*0404 DRB1*1501 DPB1*0401 DPB1*0402 Tumor express tyrosinase Tumor express NYESO1 HLA type DP4 , DP2 , DR7 allow No CNS metastases Prior CNS involvement allow provided evidence CNS disease least 2 month treatment PATIENT CHARACTERISTICS : Age 18 75 Performance status Karnofsky 70100 % Life expectancy More 16 week Hematopoietic WBC great 4,000/mm^3 Absolute neutrophil count great 2,000/mm^3 Platelet count great 100,000/mm^3 Hematocrit great 30 % Hepatic SGOT great 3 time upper limit normal INR great 1.5 due hepatic dysfunction No significant hepatic dysfunction , define hepatic toxicity grade 2 great Renal Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Calcium great 12 mg/dL Cardiovascular No significant cardiac abnormalities* , define 1 following : Congestive heart failure Clinically significant hypotension Symptoms coronary artery disease Cardiac arrhythmia present EKG require drug therapy NOTE : *Patients history cardiovascular disease abnormality undergo cardiac evaluation , include cardiac stress test and/or echocardiogram Pulmonary No clinically significant pulmonary dysfunction FEV1 least 1.0 L OR FEV1 least 60 % DLCO least 55 % ( correct hemoglobin ) Immunologic No acquired hereditary immunodeficiency No autoimmune disease No active infection No oral temperature great 38.2 degree C within past 72 hour No systemic infection require chronic maintenance suppressive therapy HIV negative Other No retinitis choroiditis No history seizures Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy ( e.g. , interleukin , interferon , melanoma vaccine , IV immunoglobulin , expand polyclonal tumorinfiltrating lymphocyte lymphokineactivated killer therapy ) Chemotherapy At least 4 week since prior chemotherapy ( standard experimental ) recover Endocrine therapy No concurrent systemic steroid except toxicity management Radiotherapy At least 4 week since prior radiotherapy Surgery Not specify Other At least 4 week since prior immunosuppressive therapy More 4 week since prior experimental drug recover No concurrent pentoxifylline No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>